Dubai: Alliance Global (AGBL Group), distributors of innovative biomedical technology and products has signed an agreement with Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis. The agreement will allow AGBL and Mission Bio to expand its product offerings into the Middle East and Africa, two key regions for Mission Bio’s growth strategy as it expands a global reach.
Darrin Crisitello, Chief Commercial Officer of Mission Bio, said, “AGBL has a history of bringing new and innovative technologies to Middle East and African countries as evidence by their success in commercializing hundreds of Next generation sequencers and supporting all the National Population genetics projects in the region. We look forward to working with their teams to bring the Tapestri platform to users throughout the region, helping meet demand for single-cell analysis and innovation."
“Mission Bio's Tapestri single-cell sequencing platform is an important addition to AGBL's portfolio of genomics products, we are very excited about the possibilities the Tapestri platform shall give our customers in developing applications for both DNA and Protein research on a single cell level"” said Dr. Tamer Degheidy, CEO of AGBL. “Access to multi-omic, single-cell sequencing technology is key to the continued enablement of our research and clinical customers across our geographies. Developing the use of the Tapestri platform in our clinical laboratories is a step we look forward to”
The latest partnership builds on Mission Bio’s commitment to provide high-quality single-cell multi-omics with the Tapestri platform globally, recently demonstrated through a strategic partnership with Sequanta Technologies Co., Ltd. to provide services to cell and gene therapy companies in mainland China. To learn more, visit missionbio.com.
-Ends-
About Mission Bio
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company’s Tapestri platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer. To learn more, visit missionbio.com.
About Alliance Global
Alliance Global is a member of the AGBL group of companies, the largest biomedical distribution group in the Middle East, Africa, and Asia region. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic centers in emerging healthcare markets. www.agbl.net
Media Contact
Consort Partners for AGBL
genomics@agbl.net
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
